Mutations and polymorphisms in complement genes have been linked with numerous rare and prevalent disorders, implicating dysregulation of complement in pathogenesis. The three common alleles of fB encode Arg (fB 32R ), Gln (fB 32Q ) or Trp (fB 32W ) at position 32 in the Ba domain. The fB 32Q allele is protective for age-related macular degeneration, the commonest cause of blindness in developed countries. fB variants purified from plasma of homozygous individuals were tested in haemolysis assays. The protective variant fB 32Q had decreased activity compared to fB 32R . Biacore comparison revealed markedly different proenzyme formation; fB 32R bound C3b with four-fold higher affinity, and formation of activated convertase was enhanced. Binding and functional differences were confirmed with recombinant fB 32R and fB 32Q ; an intermediate affinity was revealed for fB 32W . To confirm contribution of Ba to binding, affinity of Ba for C3b was determined. Ba-fB 32R had three-fold higher affinity compared to Ba-fB 32Q . We demonstrate that the disease-protective effect of fB 32Q is consequent upon decreased potential to form convertase and amplify complement activation. Knowledge of the functional consequences of polymorphisms in complement activators and regulators will aid disease prediction and inform targeting of diagnostics and therapeutics.
Introduction
Dysregulation of the alternative pathway (AP) of complement is associated with numerous pathologies, including age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), rheumatoid arthritis, Dense Deposit Disease (DDD) and lupus nephritis (1) .
The AP 'ticks over' continuously in plasma, enabling rapid response to pathogen, and also amplifies the other complement activation pathways (2) . The critical AP activation step is cleavage of C3 to C3b. The C3-cleaving enzyme, or convertase, is formed through the Mg 2+ -dependent binding of factor B (fB) to C3b, forming the proenzyme, C3bB. fB within the complex is then cleaved by a plasma serine protease, factor D (fD), releasing an amino terminal fragment, Ba (comprising 3 short consensus repeats; SCR); this fragment takes no further part in the complement cascade. Bb, comprising a serine protease domain and a von Willebrand Factor Type A (vWF-A) domain, remains bound to C3b, and is an active serine protease capable of cleaving further C3. Convertase-generated C3b can itself form more C3bBb, providing amplification of activation. As the C3b clusters around the surface-bound convertases a C5-cleaving enzyme is formed (C3bBbC3b), C5b is generated and the lytic pathway proceeds, with formation of the membrane attack complex (MAC) (3) .
To protect against the tendency of the AP to rapidly amplify, host cells express an armoury of complement regulatory proteins (CReg) which inhibit convertases or prevent MAC formation on their surfaces (4, 5) . These are either membrane-associated (CD55, CD46, CD59) or fluid phase (factor H (fH), C4b-binding protein) proteins. Dysregulation of the AP is brought about by lossof-function/expression mutations in CReg or gain-of-function mutations in components, both scenarios result in uncontrolled complement activation on self-surfaces and subsequent tissue damage and/or inflammation. The best characterised disease of AP dysregulation is aHUS, 4 where loss-of-function mutations in the CReg or gain-of-function mutations in components lead to increased complement activation at cell surfaces, resulting in renal damage (6, 7) .
More remarkably, common polymorphisms in AP components and CReg have also been linked to disease. Of particular interest are three common polymorphic variants of fB that differ at position 32 in the Ba domain (aa 7 in the mature protein; fB 32R , fB 32Q and fB 32W ; rs12614, rs641153) (8) (9) (10) . fB 32R is the most frequent allele in Caucasians (allele frequency 0.79) and was originally described as fB-S ('slow', defined by electrophoretic mobility); the fB-F ('fast') allele was further defined as fB-FA (fB 32Q ; allele frequency 0.05) and fB-FB (fB 32W ; allele frequency 0.16) (11). fB-S and fB-F, have long been associated with various pathologies, including susceptibility to pathogenic infection, for example with Trypanosoma cruzi, where fB-S is protective in cardiomyopathy associated with Chagas' disease (12) . FB-S is reported to be overrepresented in multiple sclerosis (13) , and weakly associated with Type I diabetes mellitus, where it is present in a HLA haplotype strongly linked to disease (14) . However, the most striking example of linkage of common variants in fB to disease is in AMD, the commonest cause of irreversible blindness in the elderly in the Western world (15) .
The hallmark lesion of AMD is the development of drusen, lipoproteinaceous deposits located between the retinal pigment epithelium (RPE) and Bruch´s membrane (16) . Deposition of drusen is followed by extensive atrophy of the RPE and overlaying photoreceptor cells (geographic atrophy, GA), or aberrant choroidal neovascularization (CNV). CNV under the macula is the primary cause of blindness. Although the pathogenesis of AMD is still unclear, inflammatory responses are implicated (17, 18) . AMD is a multifactorial disease, influenced by age, ethnicity, environmental and genetic risk factors (19) . Two major AMD susceptibility loci (1q31, CFH, and 10q26, LOC387715/HTRA1) that independently contribute to disease risk have been recently identified by candidate region linkage and whole genome association analyses (20-5 23) . Linkage to CFH, the gene encoding fH, was followed by reports describing association of AMD with polymorphic variations in other complement genes, fB, C3 and the factor H related genes CFHR1 and CFHR3 (24) (25) (26) (27) (28) . Remarkably, while most AMD-associated polymorphisms are linked to increased disease risk, several replication studies have demonstrated that the fB 32Q variant confers significant protection from development of AMD (26, 27, 29).
The risk allele in LOC387715 causes destabilisation of the mRNA and subsequent reduced expression of the encoded protein, a mitochondrial protein normally expressed at high levels in the retinal photoreceptor cells (30) . A functional consequence increasing risk of AMD is thus plausible. In contrast, no functional explanation of the association of any complement polymorphism with AMD has yet been provided. Here we demonstrate the functional mechanism underlying the association of fB variants with pathology. Using purified and recombinant fB variants, we demonstrate that the fB 32Q variant, identified by genetic association studies to be protective in AMD, is less efficient at forming the amplifying AP convertase. This likely protects from development of pathology in AMD and perhaps other chronic inflammatory diseases by dampening complement activation, but may predispose to infection due to reduced amplification activity.
Results

Purification of fB variants and differential activity in haemolysis assays
In order to investigate whether the R32Q polymorphism in fB influenced function, fB was purified from plasma of a donor identified by genotyping to be R32Q heterozygote. The two variants were separated by anion exchange chromatography at pH 6.0 ( Figure S1 ) and individually gel filtered on Superdex 200 equilibrated in CFD. Fractions containing pure, monomeric fB were identified and used immediately for functional analyses. In order to compare functional activity of the two variants, fB was immunodepleted from human serum 6 (NHSΔfB) and used as a source of all other complement components. Rabbit erythrocytes were incubated with NHSΔfB and different concentrations of fB variants, lysis was measured ( Figure   S2 ). The fB 32Q variant was less haemolytically active than fB 32R , at least two-fold more protein was required to achieve equivalent lysis.
To confirm and extend these data, fB was purified by affinity chromatography and gel filtration from plasma of 6 individuals identified by genotyping to be homozygote for fB 32R (three individuals), fB 32Q (two individuals) and fB 32W (one individual). The three variants showed consistent differences in hemolytic activities, with fB 32Q the least lytic and fB 32R the most lytic formed at identical fB concentrations. Decay was rapid for each variant. We have previously shown that several points of contact and conformational transitions are involved in the interaction between fB and C3b which is best modelled using a 'two-state transition' model (31) .
Analysis of sensorgrams (Figure 2 ), revealed a four-fold higher affinity of binding for fB 32R over fB 32Q ; K D calculated as a mean of three independent experiments using 'two state reaction' model: fB32R: 0.17±0.03μM, fB32Q: 0.74±0.25μM).
To analyse formation of the convertase C3bBb, fD was included with the fB variants. Although the kinetics of convertase formation by fB 32R and fB 32Q were similar, because fB 32Q bound with lower affinity, lower levels of convertase were formed ( Figure 3A ).
To investigate the half-lives of the activated convertase, purified fB variants were flowed over a C3b surface in the presence of fD. Dissociation rates (kd) are not dependent on concentration; therefore, decay curves were normalised in the y-axis. There was an obvious gradation of enzyme formation (fB 32R > fB 32W > fB 32Q ), while rates of decay of the three enzymes were identical ( Figure 3B ), as expected because Ba, containing the variant amino acid, is released from the convertase, and cannot influence decay of Bb from C3b. Formation of activated convertase using recombinant fB variants confirmed that rfB 32R generated most convertase and rfB 32Q the least, with rfB 32w intermediate ( Figure 4B) ; decay rates of Bb were identical for convertases generated by each recombinant protein.
Isolation of Ba and binding to C3b
The above data imply that variation in Ba influences proenzyme formation and the amount of enzyme formed. FB binds C3b through a multi-point contact, involving Ba and the vWF-A domain. In order to confirm differential binding of the variant Ba domains to C3b, Ba fragments were generated from purified fB 32R and fB 32Q by incubating fB and fD with C3b immobilised on Sepharose. Bb was removed on an anti-Bb affinity column, Ba was 'polished' by gel filtration and used immediately in SPR binding studies with immobilized C3b ( Figure 5A ). In contrast to fB, binding was very weak, necessitating high concentrations of Ba to determine binding affinity. Ba purified from fB 32R bound C3b with three-fold higher affinity than Ba generated from fB 32Q ( Figure 5B,C).
Effect of ionic strength on convertase formation
In order to dissect out the differences between the fB variants, enzyme formation and Ba binding were analysed in low salt concentrations. To confirm that the differential binding occurred at physiological salt, proenzyme and convertase formation by fB 32R and fB 32Q were analysed in HEPES-buffered saline (150mM). The fB 32R variant again showed a 3-4-fold higher affinity in proenzyme formation compared to fB 32Q , with resultant enhanced convertase formation ( Figure   S2 ).
Discussion
The common allotypes of fB affect risk of disease, the most striking example being AMD where fB 32Q is protective (OR 0.32; 95%CI: 0.16-0.65; unpublished data from Spanish cohort) (26, 27). The variant amino acid (aa) in fB is just 7aa from the amino terminus (25 aa leader sequence removed) within the Ba domain; a location that is paradoxical in that Ba is not part of the activated convertase and cannot therefore affect enzyme activity ( Figure 6 ). The crystal structure of fB demonstrated that Ba was folded back onto the Bb domain, with SCR2 and SCR3 9 of Ba packed tightly into an antiparallel dimer capped by SCR1, this amino-terminal SCR likely hindering access of C3b to the vWF-A domain in Bb (32) . It was suggested that initial binding of the three SCRs to C3b displaced them from the vWF-A and serine protease domains, allowing access of C3b, and triggering structural rearrangements that enabled proteolytic cleavage of fB by fD. The amino terminus of fB is unstructured and the crystal structure commences at Q 34 (aa 9 in the mature protein) (32); Q 34 (and by inference, the variant aa R 32 /Q 32 ) is in close proximity to two residues in the vWF-A domain (D 279 and F 286 ) known to affect proenzyme formation (7) ( Figure 6 ). The location of the variant aa in fB, and data indicating a binding interaction between Ba and C3b (33), led us to hypothesise that the polymorphism would affect proenzyme formation.
To test the hypothesis fB variants were isolated from plasma. In hemolysis assays using rabbit erythrocytes as target they showed differential activities, with fB 32Q being the least lytic ( Figure   1 ). The underlying mechanism was dissected using SPR. When proenzyme formation was analysed, fB 32Q bound C3b with a 4-fold lower affinity compared to fB 32R ; the fB 32W variant had an intermediate affinity (Figure 2 ). These data were confirmed using recombinant fB variants (Figure 4) . The influence of the polymorphism in the Ba domain on C3b binding was confirmed by isolating the variant Ba and directly comparing binding to C3b ( Figure 5 ). Although the affinity of Ba for C3b is weak, avidity effects from simultaneous multi-site binding in the Ba and Bb domains likely explains the striking effect of variation in Ba on apparent affinity of fB.
When effects of fB variants on formation of the activated convertase, C3bBb were studied, fB 32R generated 2.5-fold more enzyme than fB 32Q under the experimental conditions (Figure 3 ).
These data show that fB 32Q is less efficient at maintaining amplification in the AP and provide a mechanism for the observation that fB 32Q protects from pathology in AMD.
Previous investigations into functional differences between the fB variants have produced variable results. Early studies using haemolytic overlay assays indicated that fB 32Q had either decreased or equivalent functional activity compared to fB 32R (34) (35) (36) . These data were complicated by variable plasma concentrations of fB and differences in expression levels of the allele products, making quantitative comparisons difficult. A later study by Horiuchi et al.
analysed the functional activity of recombinant forms of fB 32R and fB 32Q and concluded that there was no functional difference (37) . In this study, convertase was assembled on the surface of C3b-coated sheep erythrocytes using native properdin and fD, and recombinant fB (quantified by ELISA in cell culture supernatant). We have shown that.the R32Q polymorphism influences the efficiency of proenzyme formation, rather than the activity of the convertase itself, therefore the functional difference would only be revealed if the assay reported by Horiuchi et al. was developed at a point where formation of activated convertase was incomplete and not all the fB was cleaved to Bb and stabilised by properdin. In our studies, all proteins were highly purified and polished by gel filtration into assay buffer immediately prior to each assay, the resultant sensitive assays have enabled us to establish beyond doubt functional differences between the variants.
The fB 32Q variant is apparently only protective in AMD and not in other diseases of complement dysregulation (eg. DDD, aHUS). The reasons for disease specificity are unclear. Several studies have demonstrated elevated plasma levels of complement activation products (including C3a, C3d, Ba, SC5b-9) in AMD compared to controls, indicating systemic dysregulation of complement and implying that AMD is a systemic disease with local manifestation in the retina (38, 39) . This systemic component may amplify the effects of the fB polymorphism, explaining the disease specificity. Comparative expression levels from the fB alleles in controls and AMD
are not yet available; early studies using crossed immunoelectrophoresis and radial immunodiffusion assays demonstrated a trend for higher expression from the fB 32Q allele in normal individuals (38) (39) (40) , although as with many complement components the range around the mean was large. Decreased plasma levels of the fB 32R allele product may indicate decreased expression, or increased catabolism due to AP tickover or chronic inflammatory processes. We here explain the mechanism by which a common polymorphism in a complement component protects an individual from AMD. The R32Q polymorphism in fB (rs12614, rs641153) affects risk of AMD by altering AP activity. Variations in C3 (R102G) and CFH (I62V, Y402H) are also linked to increased risk of AMD, although the functional consequences of these changes have not been characterised; early reports that fH 402H bound less well to CRP in drusen have not been substantiated (43) . Because fB 32Q is less efficient at amplifying the AP, it protects from AMD and perhaps other chronic inflammatory pathologies; however, it may have the opposite effect in infection, where fB 32Q may predispose to disease due to sub-optimal AP activation on pathogens. Indeed, the association of variants of multiple complement components or CReg with disease (for example: C3, fB, fH in AMD; fH, fI, fB, C3, CD46 in aHUS) suggest that particular combinations of variants, or 'complotypes', may combine to influence systemic complement activity in an individual, thus affecting risk of chronic inflammatory damage and susceptibility to infection. The multi-locus risk model of AMD, suggests that the effects of common variants are additive and the model can identify individuals whose lifetime risk of AMD ranges from less than 1% to more than 50% (20) (21) (22) (23) (24) (25) (26) (27) (28) . Specific variant sets of complement components and CReg can thus dramatically influence outcome, an observation that is increasingly important as the population ages, likely impacting not only in AMD, but also in other chronic inflammatory diseases such as Alzheimer's disease and atheroma. Understanding of the mechanisms underlying these associations is an essential prerequisite to the design of therapies that target complement activation in these diseases; for example, our data suggest that anti-Ba antibodies may have potential in the clinic, particularly for those individuals who carry high risk combinations of complement components and CReg.
Materials & Methods
Genotyping
Healthy volunteers were screened for mutations/polymorphisms in the CFB gene by DNA sequencing of PCR amplified fragments. Genomic DNA was prepared from peripheral blood cells according to standard procedures. Each exon of the CFB gene was amplified from genomic DNA using specific primers derived from the 5' and 3' intronic sequences as described (7) .
Sequencing was performed in an ABI 3730 sequencer using a dye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA).
Preparation of complement components and activation fragments
C3 and factor B were purified from normal human serum by classical chromatography (C3) or affinity chromatography (factor B); details are given in SI Methods. Ba was purified as a byproduct of AP activation as detailed in SI Methods. All proteins used for Biacore studies were gel-filtered into the appropriate Biacore buffer before experimentation.
Production of recombinant fB
A cDNA encoding full length fB 32R was introduced in the eukaryote expression vector pCI-Neo (Promega, Madison, WI), and R32Q and R32W aa substitutions introduced using QuickChange site-directed mutagenesis kit (Stratagen, La Jolla, CA) and appropriate primers. All fB cDNA clones were fully sequenced to confirm fidelity. CHO cells, maintained in Ham-F12 medium (GIBCO-BRL, Carlsbad, CA) supplemented with 10% fetal calf serum, L-glutamine (2 mM final concentration), penicillin and streptomycin (10 U/ml and 100 ȝg/ml), were plated in p60 plates at 5 x 10 5 cells per well. Transfections were carried out one day later with 10 ȝg of the pCI-Neo constructs and 24 ȝl of Lipofectine (Invitrogen) in a total volume of 1 ml of medium per well. Transfected cells were selected in G418 sulfate (Geneticin; GIBCO-BRL, Carlsbad, CA) at 500 ȝg/mL,. cloned by limiting dilution and clones producing the highest levels of recombinant fB (rfB) as assessed by ELISA (7), were expanded for production. rfB was purified from tissue culture supernatant by affinity chromatography on anti-Bb as described above.
Eluate was concentrated and rfB was polished by gel filtration on Superdex200 in Biacore buffer.
Haemolysis assays
NHS was depleted of fB by flowing over the JC1 anti-Bb affinity column in CFD. Run-through was collected and undiluted fractions pooled and stored at -80ºC. Use of this standard fB- and maximum.
Biosensor Analysis
All analyses were carried out on a Biacore T100 (GE Healthcare). C3b was amine coupled to the sensor chip as instructed by the manufacturers (NHS/EDC coupling kit). In the example illustrated in figures 2 and 3, 880RU C3b are immobilised, although replicate experiments used differing amounts. In figure 4 , 458RU C3b are immobilised. For kinetic analyses a CM5
(carboxymethylated dextran) chip was used and data collected at 25°C at a flow rate of 30μl/minute; data from a reference cell was subtracted to control for bulk refractive index changes. Samples were injected using the KINJECT command to ensure accurate association kinetics. To analyse proenzyme formation, fB variants were flowed across the C3b surface at different concentrations; the surface was regenerated with EDTA containing buffer as previously described (31) . To analyse formation of the activated convertase, fD was incuded at 1μg/ml and the surface was regenerated using soluble recombinant CD55 (31) (gift of Dr Susan Lea, Oxford, UK). In the case of Ba, no regeneration step was required. Due to the low affinity of the Ba interaction, high levels of C3b (4058RU) were immobilised and steady state analysis was used to quantitate affinity. Data were evaluated using Biaevaluation T100 evaluation software (Version 1.1), global fitting was used to determine kinetic parameters that fitted all curves (differing concentrations of fB) within an experiment. Concentration of analytes was assessed using absorbance at A 280 , molarities were calculated using the following extinction coefficients (molecular masses and coefficients obtained using Protean software, DNAStar): factor B (1.43), Ba (1.74).
Figure Legends proteins were purified from the plasma of donors known to be homozygous for fB 32R or fB 32Q .
FB was flowed over the surface of the C3b-coated chip in the presence of 1μg/ml fD at concentrations between 460nM and 7nM in Biacore buffer (10mM HEPES pH7.4, 50mM NaCl, 
